DE60332011D1 - Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein") - Google Patents

Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")

Info

Publication number
DE60332011D1
DE60332011D1 DE60332011T DE60332011T DE60332011D1 DE 60332011 D1 DE60332011 D1 DE 60332011D1 DE 60332011 T DE60332011 T DE 60332011T DE 60332011 T DE60332011 T DE 60332011T DE 60332011 D1 DE60332011 D1 DE 60332011D1
Authority
DE
Germany
Prior art keywords
factor viii
lrp
interaction
antagonists
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332011T
Other languages
German (de)
English (en)
Inventor
Koenraad Mertens
Arend Niels Bovenschen
Jan Voorberg
Manfred Rieger
Friedrich Scheiflinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanquin
Original Assignee
Sanquin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin filed Critical Sanquin
Application granted granted Critical
Publication of DE60332011D1 publication Critical patent/DE60332011D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60332011T 2002-04-29 2003-04-28 Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein") Expired - Lifetime DE60332011D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37635102P 2002-04-29 2002-04-29
PCT/EP2003/004425 WO2003093313A2 (en) 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein

Publications (1)

Publication Number Publication Date
DE60332011D1 true DE60332011D1 (de) 2010-05-20

Family

ID=29401334

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332011T Expired - Lifetime DE60332011D1 (de) 2002-04-29 2003-04-28 Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")

Country Status (10)

Country Link
US (1) US8586538B2 (enExample)
EP (1) EP1497330B1 (enExample)
JP (2) JP2005535588A (enExample)
AT (1) ATE463514T1 (enExample)
AU (1) AU2003227687B2 (enExample)
CA (1) CA2484155C (enExample)
DE (1) DE60332011D1 (enExample)
DK (1) DK1497330T3 (enExample)
ES (1) ES2343681T3 (enExample)
WO (1) WO2003093313A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006003183A1 (de) * 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
JP5674650B2 (ja) * 2008-06-04 2015-02-25 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
JP5394864B2 (ja) * 2009-09-10 2014-01-22 アスモ株式会社 モータ
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507664A (ja) * 1995-06-12 1999-07-06 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
AU760678B2 (en) * 1998-05-08 2003-05-22 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DK1129186T4 (da) * 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet

Also Published As

Publication number Publication date
CA2484155A1 (en) 2003-11-13
JP2010202664A (ja) 2010-09-16
US20080219983A1 (en) 2008-09-11
CA2484155C (en) 2015-10-13
ATE463514T1 (de) 2010-04-15
EP1497330B1 (en) 2010-04-07
WO2003093313A3 (en) 2004-07-29
WO2003093313A2 (en) 2003-11-13
DK1497330T3 (da) 2010-06-14
EP1497330A2 (en) 2005-01-19
AU2003227687A1 (en) 2003-11-17
AU2003227687B2 (en) 2009-10-15
ES2343681T3 (es) 2010-08-06
JP2005535588A (ja) 2005-11-24
US8586538B2 (en) 2013-11-19

Similar Documents

Publication Publication Date Title
ATE463514T1 (de) ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß)
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
DE60032486D1 (de) Prion protein peptide und deren verwendung
EA200500782A1 (ru) Лечение геморрагического шока
TR200000913T2 (tr) Tıbbi maddeler
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
ATE318601T1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE506375T1 (de) Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
MA31941B1 (fr) Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine
WO2004075838A3 (en) Method and compositions for the treatment of meconium aspiration syndrome
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
DE69720241D1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
ATE386050T1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
SE9902597D0 (sv) New use
HUP0001913A2 (hu) Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
ATE430578T1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
ATE506947T1 (de) Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition